BioSpace News Archive

Eloxx Pharmaceuticals, Inc. today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET.

CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.

Chemomab Therapeutics Ltd. today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

BioLineRx Ltd. today announced a collaboration with Washington University School of Medicine in St. Louis to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of the Company’s lead clinical candidate motixafortide to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD), one of the most common genetic diseases globally.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.

Sensei Biotherapeutics, Inc. today announced that Company management will present at Oppenheimer’s 33rd Annual Healthcare Conference.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California.

Olink Holding AB announced that the Yong Loo Lin School of Medicine, National University of Singapore has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink® Explore 3072, Olink® Explore 1536, Olink® Target 96 and Target 48, and the recently launched Olink® Flex platforms.

Medexus Pharmaceuticals is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023.

Amarin Corporation plc highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.